Your browser doesn't support javascript.
loading
Impact of monthly headache days on migraine-related quality of life: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study.
Lipton, Richard B; Pozo-Rosich, Patricia; Orr, Serena L; Reed, Michael L; Fanning, Kristina M; Dabruzzo, Brett; Buse, Dawn C.
Afiliación
  • Lipton RB; Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, USA.
  • Pozo-Rosich P; Headache Unit, Neurology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Orr SL; Headache Research Group, VHIR, Universitat Autonoma de Barcelona, Barcelona, Spain.
  • Reed ML; Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada.
  • Fanning KM; Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Dabruzzo B; Vedanta Research, Chapel Hill, North Carolina, USA.
  • Buse DC; MIST Research, Wilmington, North Carolina, USA.
Headache ; 63(10): 1448-1457, 2023.
Article en En | MEDLINE | ID: mdl-37795746
OBJECTIVE: To characterize the direct impact of monthly headache days (MHDs) on health-related quality of life (HRQoL) in people with migraine and the potential mediating effects of anxiety, depression, and allodynia. BACKGROUND: Although the general relationship between increased migraine frequency (i.e., MHDs) and reduced HRQoL is well established, the degree to which reduced HRQoL is due to a direct effect of increased MHDs or attributable to mediating factors remains uncertain. METHODS: Cross-sectional baseline data from participants with migraine who completed the Core and Comorbidities/Endophenotypes modules in the 2012-2013 US Chronic Migraine Epidemiology and Outcomes (CaMEO) study, a longitudinal web-based survey study, were analyzed. The potential contribution of depression, anxiety, and/or allodynia to the observed effects of MHDs on HRQoL as measured by the Migraine-Specific Quality-of-Life Questionnaire version 2.1 (MSQ) was evaluated. RESULTS: A total of 12,715 respondents were included in the analyses. The MSQ domain scores demonstrated progressive declines with increasing MHD categories (B = -1.23 to -0.60; p < 0.001). The observed HRQoL decrements associated with increasing MHDs were partially mediated by the presence of depression, anxiety, and allodynia. The MHD values predicted 24.0%-32.4% of the observed variation in the MSQ domains. Depression mediated 15.2%-24.3%, allodynia mediated 9.6%-16.1%, and anxiety mediated 2.3%-6.0% of the observed MHD effects on the MSQ. CONCLUSIONS: Increased MHD values were associated with lower MSQ scores; the impact of MHDs on the MSQ domain scores was partially mediated by the presence of depression, anxiety, and allodynia. MHDs remain the predominant driver of the MSQ variation; moreover, most of the variation in the MSQ remains unexplained by the variables we analyzed. Future longitudinal analyses and studies may help clarify the contribution of MHDs, comorbidities, and other factors to changes in HRQoL.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Calidad de Vida / Trastornos Migrañosos Tipo de estudio: Prognostic_studies / Screening_studies Límite: Humans Idioma: En Revista: Headache Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Calidad de Vida / Trastornos Migrañosos Tipo de estudio: Prognostic_studies / Screening_studies Límite: Humans Idioma: En Revista: Headache Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos